<?xml version="1.0" encoding="UTF-8"?>
<p id="p0020">On the other hand, in opposition to the broad characteristic of a zoonosis, the second SARS-CoV-2 feature which attracted much attention is the surface spike glycoprotein, or S protein, as it binds with high efficiency to the host cell angiotensin-converting enzyme 2 (ACE2), mainly present in the heart and the lungs. Moreover, it requires cleavage by the host serine protease TPRSS2 for internalisation [
 <xref rid="bib9" ref-type="bibr">9</xref>]. As a direct consequence, much research has focused on the S protein in the role of a vaccine antigen or a target for blocking fusion with the host cell [
 <xref rid="bib10" ref-type="bibr">10</xref>], a topic further elaborated by several articles in this issue of the 
 <italic>Biomedical Journal</italic> [
 <xref rid="bib11" ref-type="bibr">[11]</xref>, 
 <xref rid="bib12" ref-type="bibr">[12]</xref>, 
 <xref rid="bib13" ref-type="bibr">[13]</xref>].
</p>
